Ruifeng Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ruifeng Xue has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chujie Bai
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Beijing, China
1 shared publication - Jiayong Liu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China
1 shared publication - Lu Zhang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Beijing, China
1 shared publication - Shu Li
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China
1 shared publication - Tian Gao
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China
1 shared publication Xinyu Wang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
The efficacy and predictive value of 99mTc-rituximab for sentinel lymph node biopsy in acral melanoma patients
We sought to evaluate the efficacy and predictive value of 99mTc-rituximab as a tracer for sentinel lymph node biopsy (SLNB) in acral melanoma (AM) patient
- 12 May 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Open AccessThe efficacy and predictive value of 99mTc-rituximab for sentinel lymph node biopsy in acral melanoma patients
We sought to evaluate the efficacy and predictive value of 99mTc-rituximab as a tracer for sentinel lymph node biopsy (SLNB) in acral melanoma (AM) patient